Clinical trial of Lu-177- HEDMP for bone pain palliation of bone metastasis in breast cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201109217611N1

Enrollment

Registered

2014-03-20

Start date

2010-03-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

BREAST CANCER. Malignant neoplasm of breast

Interventions

?Single dose slow IV injection of 0.8 mci/kg of Lu177 EDTMP and follow-up by questiunare and CBC measurement.

Treatment - Drugs

?Single dose slow IV injection of 0.8 mci/kg of Lu177 EDTMP and follow-up by questiunare and CBC measurement

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria:Severe metastatic bone pain in breast cancer; positive bone scan in recent 1 month corresponding to the painful regions ; normal recent CBC (WBC>2400/ul--Platelet>60000/UL) Exclusion criteria: Negative bone scan ; Pathological fracture of the vertebrae ; WBC<2400/ul---Platelet<60000/ul ; incooperative patients

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
SEVERITY OF PAIN. Timepoint: every 2 weeks up to 12 weeks. Method of measurement: questionnaire-By call.	—

Secondary

Measure	Time frame
Reduced morbidity- reduce sedative consumption. Timepoint: 12 weeks after drug administration. Method of measurement: questionnare.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehrossadat Alavi

Nuclear medicine departement, Shiraz University of Medical Sciences

alavimh@sums.ac.ir+98 71 1612 5319

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026